The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
Background CD47 is a broadly expressed cell surface glycoprotein associated with immune evasion. Interaction with the inhibitory receptor signal regulatory protein alpha (SIRPα), primarily expressed on myeloid cells, normally serves to restrict effector function (eg, phagocytosis and immune cell hom...
Saved in:
| Main Authors: | Li Zhang, Emmanuel Normant, Ammar Adam, Marisa O Peluso, Caroline M Armet, Rachel W O’Connor, Benjamin H Lee, Andrew C Lake, Scott C Chappel, Jonathan A Hill, Vito J Palombella, Pamela M Holland, Alison M Paterson |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000413.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Facilitating cholangiocarcinoma inhibition by targeting CD47
by: Kulthida Vaeteewoottacharn, et al.
Published: (2024-12-01) -
Dual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8+ T cells
by: Susan N Christo, et al.
Published: (2024-01-01) -
Imaging of CD47 Expression in Xenograft and Allograft Tumor Models
by: Alexander Zheleznyak, et al.
Published: (2013-11-01) -
Blocking ANGPTL3 and CD47 impact on atherosclerosis-correspondence
by: Han-Yong Hou, et al.
Published: (2025-02-01) -
CD47 in Osteosarcoma: Correlation with Metastasis and Macrophage-Mediated Phagocytosis
by: Yunmi Ko, et al.
Published: (2024-11-01)